Compare CVBF & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CVBF | ACAD |
|---|---|---|
| Founded | 1974 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.3B |
| IPO Year | 2009 | 2000 |
| Metric | CVBF | ACAD |
|---|---|---|
| Price | $22.66 | $24.84 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 22 |
| Target Price | $24.50 | ★ $30.55 |
| AVG Volume (30 Days) | 1.6M | ★ 1.7M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.95% | N/A |
| EPS Growth | 5.56 | ★ 69.12 |
| EPS | ★ 0.38 | 0.02 |
| Revenue | N/A | ★ $726,437,000.00 |
| Revenue This Year | $21.47 | $18.80 |
| Revenue Next Year | $15.21 | $11.70 |
| P/E Ratio | ★ $58.84 | $1,241.50 |
| Revenue Growth | N/A | ★ 40.45 |
| 52 Week Low | $17.95 | $19.69 |
| 52 Week High | $23.37 | $28.35 |
| Indicator | CVBF | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 55.84 | 51.72 |
| Support Level | $22.01 | $20.56 |
| Resistance Level | $23.35 | $25.36 |
| Average True Range (ATR) | 0.45 | 0.76 |
| MACD | -0.10 | -0.26 |
| Stochastic Oscillator | 53.50 | 23.84 |
CVB Financial Corp is the holding company for Citizens Business Bank. Citizens Business Bank offers banking, lending, and investing services. It provides a full complement of lending products, including commercial, agribusiness, consumer, SBA, real estate, and construction loans, as well as equipment and vehicle leasing. Commercial products include lines of credit and other working capital financing, accounts receivable lending and letters of credit. It is a community bank with one reportable operating segment.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.